Fig. 3: Glut2 is required for optimal CD8+ T cell-mediated anti-allograft and anti-tumour immunity.
From: The glucose transporter 2 regulates CD8+ T cell function via environment sensing
a,b, Glut2+ or Glut2− female mice received skin grafts from female B6.Kd donors, to avoid confounders due to anti-HY responses (a). CD8+ T cell depletion was achieved by IP injection of 200 μg anti-CD8 at days –1 and 1 (b). P values of the mean time of rejection are indicated within the graphs (n = 8–10, N = 1). c, EO771 cells were injected into the mammary glands of female Glut2+ or Glut2− C57BL/6J mice (n = 10). The mean values of tumour volume (mm3) are reported (±s.d., n = 10, N = 1). d–f, Tumour tissue was embedded in paraffin for H&E staining (d) for assessment of necrosis score (e) and the percentage of TILs (f) (±s.d., n = 6, N = 1). g–i, Immunofluorescence staining of CD3, CD4, CD8 and DAPI in OCT-embedded tumour sections was analysed and quantified for the percentage of CD3+CD4+ T cells (h), and the percentage of CD3+CD8+ T cells (i) (±s.d., n = 7, N = 1). j,k, T cells from tumour and spleen were assessed for surface expression of Glut2 (j) and Glut1 (k) by flow cytometry. Delta changes of MFI in Glut2 and Glut1 expression (±s.d.; n = 10, N = 1) were determined by subtraction of isotype control from antibody staining. a,b, log-rank (Mantel–Cox) test; c–k, unpaired, two-tailed Student’s t-test.
